by Plus Therapeutics | Dec 16, 2025 | Uncategorized
What Are Targeted Radiotherapeutics? Targeted radiotherapeutics are designed to deliver radiation from within the body, directly to tumor sites, using advanced targeting mechanisms that guide radioactive payloads to cancer cells with high precision. Unlike traditional...
by Plus Therapeutics | Dec 4, 2025 | Uncategorized
Plus Therapeutics is pleased to announce the presentation of three positive clinical data updates at the World Federation of Neuro-Oncology Societies (WFNOS) / Society for Neuro-Oncology (SNO) 2025 Annual Meeting. These new findings advance the Company’s growing body...
by Plus Therapeutics | Dec 3, 2025 | Uncategorized
Plus Therapeutics’ growing momentum in central nervous system (CNS) oncology was recently spotlighted when President & CEO Marc Hedrick, MD, joined host Ira S. Pastor on the Progress, Potential, and Possibilities podcast. The in-depth discussion provides a clear,...
by Plus Therapeutics | Nov 19, 2025 | Uncategorized
Plus Therapeutics is pleased to announce that the Company will present three new clinical data updates at this year’s World Federation of Neuro-Oncology Societies (WFNOS) / Society for Neuro-Oncology (SNO) Annual Meeting. The conference, one of the largest global...
by Plus Therapeutics | Nov 5, 2025 | Uncategorized
Plus Therapeutics President & CEO, Marc Hedrick, MD, recently joined Nicole R. on the pharmaphorum podcast for an in-depth conversation about how the Company is developing next-generation radiotherapeutics designed to address some of the most difficult-to-treat...
by Plus Therapeutics | Nov 3, 2025 | Uncategorized
Plus Therapeutics (NASDAQ: PSTV) was recently highlighted in an article by Mary Caffrey in The American Journal of Managed Care (AJMC) — one of the leading peer-reviewed journals covering the intersection of clinical innovation, policy, and patient access. The...
Recent Comments